The FDA has approved Axsome Therapeutics’ Auvelity for major depressive disorder (MDD) in adults, making it the first and only oral N-methyl D-aspartate (NMDA) receptor antagonist approved for this indication.
https://www.pharmalive.com/wp-content/uploads/2022/04/BioSpaceFDAlogo4-25-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-08-19 11:25:022022-08-19 11:25:02Axsome's Auvelity becomes first FDA-approved oral NMDA for major depressive disorder
